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Introduction
Liver regeneration is an essential component of the repara-
tive process following liver injury and surgical resection in
man [1]. In its absence, morbidity and mortality rates are
often increased. The capacity for hepatic regeneration after
hepatectomy is important for allowing surgeons to deter-
mine the appropriate extent of resection. Post-hepatectomy
liver insufficiency is one of the most serious problems asso-
ciated with liver surgery, especially in the cirrhotic liver,
which has less function reserve than the normal liver [2].
Since hepatocellular carcinoma (HCC) is often seen in
cirrhotic livers, the morbidity and mortality rates after
hepatectomy are higher in these patients [3]. Insufficient
regeneration and dysfunction of cirrhotic liver following
partial hepatectomy (PH) often make the patients vulner-
able to postoperative liver failure, which frequently leads to
multiple organ failure. In operations for HCC, the degree of
underlying liver cirrhosis limits the extent of safe hepatic
resection.
Experimental hepatic cirrhosis has been induced in rats
with chronic administration of hepatotoxins such as carbon
tetrachloride (CCI4), dimethylnitrosamine (DMN) or
thioacetamide (TAA) [1, 4–6]. These animal models
mimic, to various degrees, the pathological processes
observed in human hepatic fibrosis. TAA is a well known
hepatotoxin and has been used in studying liver pathology.
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Background
Post-hepatectomy liver insufficiency is one of the most
serious postoperative problems and its prevention is
important after major hepatic resection, especially in the
cirrhotic liver. Some growth factors and cytokines appear
to play important roles in liver regeneration. In the present
study we have investigated the effects of granulocyte-
macrophage colony-stimulating factor (GM-CSF) on
hepatic regeneration after 70% partial hepatectomy (PH)
in cirrhotic and non-cirrhotic rats.
Methods
A rat model of liver cirrhosis was prepared using thioac-
etamide (TAA) (a dose of 20 mg/100 g body w, intra-
peritoneally) on three days a week for 12 weeks. Adult
male rats were divided into four groups:Group 1 (n = 10) no
cirrhosis and no GM-CSF; Group 2 (n = 10) no cirrhosis
and GM-CSF; Group 3 (n = 10) cirrhosis and no GM-CSF;
and Group 4 (n = 10) cirrhosis and GM-CSF. All the rats
underwent a 70% hepatectomy, and GM-CSF was admin-
istrated immediately after operation in Groups 2 and 4. On
postoperative days 2 and 7, fresh samples from the rem-
nant liver were obtained to evaluate its regenerative capac-
ity.The liver regenerative process was estimated by DNA
synthesis, using flow cytometry.
Results
Proliferation index (PI) of hepatocytes at 48 h was higher
in Group 4 rats than Group 3 rats (p < 0.05). On post-
operative day 7, PI was elevated in Group 3 rats compared
with Group 4 rats, but this difference was not statistically
significant. In non-cirrhotic rats given GM-CSF, PI was
increased compared with Group 1 rats at day 2 (p < 0.05),
but not at day 7.
Conclusions
The findings suggest that the proliferative capacity of liver
cells is impaired and delayed after 70% PH in cirrhotic rat
liver. GM-CSF administration might enhance the liver PI in
both normal and TAA-induced cirrhotic rats.
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It causes hepatic centrilobular necrosis after acute adminis-
tration, while its chronic administration induces liver cir-
rhosis and bile duct carcinoma in a rat model [5–9].
Prevention of postoperative hepatic failure is important
after liver resection. Hepatic regeneration is a physiological
mechanism that leads to restoration of remnant hepatic
parenchyma after partial hepatectomy (PH). This process is
mediated by a variety of cytokines and growth factors
[1,2,7,10–15]. Hepatocyte growth factor (HGF) was origi-
nally identified as the most potent stimulator of DNA
synthesis in primary hepatocytes [16].
The liver is the target organ for many cytokines, and
some cytokines are known to affect the proliferation of
hepatocytes [1,17,18]. Many growth factors and cytokines,
including HGF, epidermal growth factor, transforming
growth factor- b interleukin-6 (IL-6), tumour necrosis
factor- a (TNF- a ), insulin and noradrenaline (norepineph-
rine), appear to play important roles in liver regenerative
capacity in response to loss of hepatic parenchyma.
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a cytokine able to regulate a number of func-
tions. It was first identified as the most potent mitogen for
bone marrow [19], but also has been used in local treatment
of impaired wound healing [20]. It not only influences the
proliferation and differentiation of stem cells, but also reg-
ulates some other cells involved in acute and chronic
inflammation [20,21]. We have previously demonstrated
that GM-CSF therapy improves radiation-impaired wound
healing in rats [22]. To our knowledge, there has been no
previous report on the effect of GM-CSF on hepatic regen-
eration after PH. We have therefore developed an animal
model and investigated its effect on hepatic regeneration
after 70% PH in normal and TAA-induced cirrhotic rats.
Material and methods
Male Wistar rats (n = 85) weighing 240–285 g were obtained
from the Refik Saydam Central Institute of Hygiene, Drug
and Cosmetic Research Department, Ankara, Turkey for use
in this study. The study was approved by the local ethics
committee. The rats were randomly selected and assigned
to experimental groups. Animals were kept in an air-
conditioned room at 21°C, received humane care and were
given a standard rat diet and water ad libitum under standard
environmental conditions.
Liver cirrhosis was induced in 60 rats by administrating
TAA (Sigma Chemical Co. St. Louis, MO). Rats in the
cirrhosis groups received intraperitoneal injections of a
sterile solution of TAA dissolved in 0.15 mol/liter NaCI
(40 mg/ml) at a dose of 20 mg/100 g body wt and adminis-
tered three times per week for up to 12 weeks. Animals
were then rested for 2 weeks to allow TAA washout before
operation. They had no additional treatment during the
study period. Animals were fasted for 12 h before 70% PH
(70% hepatectomy comprised removal of the left lateral
and median lobes).
The animals were anaesthetised with an intramuscular
injection of ketamine hydrochloride (100 mg/kg) (Ketalar,
Parke-Davis, Morris Plains, NJ, USA). All the normal and
TAA-induced cirrhotic rats were subjected to 70% PH,
according to the technique of Higgins and Anderson [23].
Under anaesthesia, a midline incision was made in the sub-
xiphoid area, the abdomen was opened and the liver was
mobilised. The median and lateral lobes were then
removed.
Rats were divided into four groups: Group 1 had no cir-
rhosis and no GM-CSF; Group 2 had no cirrhosis but
received GM-CSF; Group 3 had cirrhosis but no GM-CSF;
and Group 4 had both cirrhosis and GM-CSF.
Recombinant human GM-CSF (rh-GM-CSF) was kindly
provided by Novartis (Ankara, Turkey) in the form of
Leucomax (lyophilized powder with reconstitution fluid).
rh-GM-CSF (40 l /ml) was injected subcutaneously imme-
diately after hepatectomy in Group 2 and 4 rats.
Hepatic regeneration was documented by determining
DNA synthesis by flow cytometry at various time points
after PH. On postoperative day 2 and 7, fresh biopsy speci-
mens were obtained from the rats. The specimens were
stored at 230°C until flow-cytometric analysis of DNA
synthesis.
Separation of nuclei
Liver tissues were mechanically divided into millimetre
pieces, which were digested with 1 mg/ml protease (Sigma
type XXIV) at 37°C for 30 minutes with manual shaking
every 5–10 minutes. Following digestion, 2 ml cold PBS
was added to the solution. The solution was filtered
through a 37- l m nylon mesh. After two washings with cold
PBS, cell suspensions (with 5 3 10
5 to 1 3 10
6 nuclei per
ml) were prepared with trypsin buffer and were centrifuged.
The nuclei were then incubated with RNAse solution for
10 minutes. Finally, the nuclear suspensions were stained
with propidium iodide and were kept in the dark for at least
10 minutes at 4°C. Samples were filtered through a 37- l m
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nylon mesh before flow cytometric analysis. Since we could
not purify the liver cells separately, the nuclei obtained
from digested liver tissues included Kupffer cells as well as
hepatocytes.
Flow cytometry
DNA analyses were performed with a FacSort flow cytom-
etry (Becton & Dickinson) equipped with a 2 W argon-
laser. Excitation of propidium iodid occurred at 488 nm. At
least 15,000–20,000 nuclei from each specimen were
analysed.
DNA histograms having only one G0/G1 peak with a
coefficient of variation (CV) of less than 5% were defined
as diploid [24]. DNA peaks with a CV of more than 9%
were not evaluated. The histograms with CV between 5%
and 9% were accepted as ‘wide-diploid’ and were then col-
lected in the same group with diploid ones. The liver tis-
sues were classified as aneuploid if there were at least two
distinct G0/G1 peaks; the latter having at least 10% of
total counts. Aneuploid tissues with a DNA index (DI)
between 1.9 and 2.1 were classified as tetraploid, and
those with a DI >2.1 as hypertetrapooid. Cell cycle analy-
ses were carried out with MODFIT software (Becton &
Dickinson). DNA histograms having a CV of more than
8% were not evaluated for s-phase fraction (SPF) meas-
urement [25].
The liver proliferation index (PI) expressed as G2 +
SPF/M was compared between the groups. The Wilcoxon
test for unpaired measurements was used to analyse the
data. Differences between samples were considered signifi-
cant when p value was less than 0.05. The statistical analy-
sis was performed by Statistical Package for Social Sciences
(SPSS for MS Windows Release 7.0, Chicago, IL, USA).
Results
TAA was given to 60 rats, 18 of which died during the
period of administration. Because TAA induces anorexia,
pair-fed control rats were given the same amount of labora-
tory chow as that consumed by the TAA-treated rats on the
previous day, to equalise the nutritional status between
groups. After the designated period of TAA injection, ani-
mals were kept for two weeks to allow the washout of TAA.
During the 12-week period of TAA injection, the mean
body weight of TAA-treated rats was officially lower than
that of controls.
The livers of the surviving rats were shown to have the
pathological criteria of cirrhosis microscopically. Cirrhosis
was evaluated before the start of GM-CSF treatment. The
cirrhotic liver was deformed and had a relatively small lobe.
The liver was pale, with irregular large regeneration nod-
ules. The histological appearance of liver exposed to TAA
for 12 weeks is shown in Figure 1. The lobular architecture
was disrupted, and pseudonodular formation was observed
with wide collagen bands extending between the portal
areas. Portal fibrosis became more advanced, and bridging
fibrosis was also seen.
The PI of hepatocytes at 48 h after 70% PH was meas-
ured in normal and TAA-induced cirrhotic rats. The PI in
normal rats treated with GM-CSF (Group 2) was higher
than that of the normal controls (Table 1). However, there
was no statistically significant difference between the
groups at postoperative day 7. In cirrhotic rats give GM-
CSF (Group 4), PI was increased compared to Group 3 at
postoperative day 2 (p <0.01) (Table 2). The mean PI on
day 7 in the GM-CSF-treated and control cirrhotic rats
were 6.5% and 13.7%, respectively. Although this PI
was higher in Group 3, the difference was not statistically
significant (p >0.05). In addition, in GM-CSF-treated
cirrhotic rats the PI on postoperative days 2 and 7 was
18.9% and 6.5%, respectively (p = 0.004). There was no
significant difference between the groups for DNA
histograms.
Eleven rats submitted to a 70% hepatectomy died within
48 h. Four rats in Group 4 died shortly after the procedure
and seven in Group 3. Although the mortality rate was
higher in Group 3 than Group 4, this difference was not
statistically significant (Pearson chi-square test, p >0.05).
69
Effect of GM-CSF on liver regeneration
Figure 1. Section of liver tissue from a rat adminstered TAA for 12 weeks
(H&E; original magnification 3100).
Postmortem examination of these animals revealed severe
ascites and portal congestion, suggesting that sequestration
of blood in the splanchnic bed was the cause of death. The
data show that the GM-CSF administration not only
improved hepatocellular regenerative capacity, but also
might suppress the onset of postoperative liver failure.
Discussion
Cirrhotic livers are thought to display less regenerative
capacity than normal livers after hepatic resection [1–3]. In
patients with cirrhosis, impaired liver function and regen-
erative capacity after major hepatic resection are associated
with increased morbidity and mortality rates [1–3,26]. In a
cirrhotic liver, the regenerative ability and the specific
functions are so impaired that excessive resection can easily
produce postoperative liver dysfunction, which frequently
leads to life-threatening multiple organ failure.
Liver cell proliferation after PH in healthy rats has been
thoroughly investigated [1,27]. PH is a good model of com-
pensatory cellular growth, and  70% resection has been
widely used to initiate a proliferative hepatocyte response
[28]. Liver regeneration is impaired and delayed after 70%
PH in a cirrhotic liver; the process is prolonged and the
functional capacity is impaired [3].
In the present study cirrhosis was established by the
administration of TAA. This well-known hepatotoxin has
been used widely in studying liver pathology [5–9]. Several
reports have shown that liver damage caused in rats by
chronic TAA administration resembles human cirrhosis in
both biological and morphological aspects [5,8,29]. Acute
and chronic administration of TAA leads to liver necrosis,
cirrhosis and carcinoma in rats [5–9,29].
The liver has a marked regenerative capacity [1].
Regeneration is mainly a result of hyperplasia and has a
rapid onset. The onset of DNA synthesis in hepatocytes
occurs 12–16 h posthepatectomy with a peak level at 24 h,
followed by a peak of mitosis at 32–34 h; the mass of the
liver is restored within 7–10 days. Following PH the major
wave of DNA synthesis starts 14 h after operation and
reaches a peak by 24 h [30]. As previously demonstrated,
the liver mass is restored in rats with extraordinary rapidity,
the residual lobes nearly doubling in size by 48 h and
approaching the original liver weight by 7 days [31]. We
estimated PI from remnant liver tissue samples on postop-
erative days 2 and 7.
Many tissue-based and serum-based methods are
presently employed in clinical and experimental animals to
evaluate liver regeneration [27,32], but a ‘gold standard’ has
yet to be identified. DNA synthesis can be measured by a
variety of techniques. Flow cytometry is an accurate and
objective method of monitoring hepatic regenerative activ-
ity [29,33,34]. The S phase refers to the DNA synthesis
phase of the cell cycle. Following the S phase is the G2
phase, during which the cell prepared for mitosis or physi-
cal cell division [35]. The principal advantage of this
method is that the information obtained is objective and
represents measurements on large numbers of nuclei and/or
cells, but disadvantages include the cost of the sophisti-
cated equipment required that is not generally available in
A ErogÏlu et al.
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Table 2. Proliferation index (PI) in Group 3 and Group 4
PI Group 3 Group 4 p value
Postoperative day 2 8.8% (1.3–19.5)* 18.9% (12.6–26.7) 0.02
Postoperative day 7 13.7% (1.1–20.9) 6.5% (2.7–13.9) NS
* values in parentheses are range
NS: not significant
Table 1. Proliferation index (PI) in Group 1 and Group 2
PI Group 1 Group 2 p value
Postoperative day 2 7.6% (2.9–12.3)* 11.2% (2.5–20.7) 0.04
Postoperative day 7 7.1% (2.4–20.7) 9.6% (2.9–22.3) NS
* values in parentheses are range
NS: not significant
many laboratories and the need to disrupt tissue resulting
in the loss of relationships between cell subpopulation
[36].
Several cytokines including GM-CSF, IL-2, IL-3 and
IL-6 have been shown to induce proliferation of macro-
phages or their precursors in bone marrow and various
other organs, both in vivo and in vitro [37–39]. Hemato-
poietic cytokines such as granulocyte colony-stimulating
factor (G-CSF) and GM-CSF can enhance the immune
response in several ways [38–41]. These agents stimulate
proliferation and differentiation of granulocytes, macro-
phages, monocytes and eosinophils from pluripotent stem
cells.
Previously Sakamoto and colleagues demonstrated that
cultured murine parenchymal liver cells produce GM-CSF
[42]. They also suggested that hepatocytes might play a role
in the regional haematolymphoid system of the liver. Some
authors have shown that treatments such as GM-CSF have
antiviral and immunoregulatory effects in patients with
chronic hepatitis B [43]. Hoedemakers & associates indi-
cated that GM-CSF plays an important role in the in-vitro
proliferation of rat liver macrophages [39]; more recently,
Theocharis and co-workers have reported that G-CSF can
augment liver regenerative capacity [7]. Based on these
reports, GM-CSF was used as a hepatotrophic factor in an
attempt to stimulate DNA synthesis after 70% PH in the
rat model.
The effect of GM-CSF on hepatic regeneration after
70% PH was evaluated in normal and TAA-induced cir-
rhotic rats. To our knowledge, this is the first report testing
the effect of GM-CSF on liver regeneration via flow cyto-
metric analysis of DNA content. On postoperative day 2,
the PI of hepatocytes in the remaining cirrhotic liver was
higher in the GM-CSF-treated rats than the controls. A
similar finding was seen in non-cirrhotic rats. These results
indicate that exogenous GM-CSF administration promotes
the hepatocellular DNA synthesis.
It is well known that GM-CSF acts as a potent growth
factor, stimulating both the proliferation and maturation of
myeloid progenitor cells. Yet the mechanism of action of
GM-CSF on hepatocellular proliferation remains unclear.
It could exert a direct as well as an indirect effect on the
liver, through the cytokine cascade. Sakamoto and col-
leagues studied whether the liver could function as one of
the haematolymphoid organs during postresectional regen-
eration [44]. They found proliferation of the intrahepatic
lymphocyte-rich fraction with GM-CSF. The proliferative
response to the cytokines was augmented, while liver
regeneration affected the systemic haematolymphoid
system.
Liver regeneration after PH involves proliferation of
cells in the remaining organ including hepatocytes, Kupffer
cells, biliary epithelial cells, Ito cells and fenestrated
endothelial cells [1,2,27]. Colony-stimulating factors such
as GM-CSF can induce the proliferation of Kupffer cells
[45,46]. Thus the number of Kupffer cells increased four-to-
six-fold after stimulation with GM-CSF [45]. Although we
could not separate hepatocytes from Kupffer cells, GM-CSF
administration in TAA-induced cirrhotic rats enhanced
liver cell proliferation and ameliorated their suppressed
regenerative capacity. Based on previously published data
and our findings, it is suggested that administration of
GM-CSF as an exogenous hepatotrophic factor may play a
useful role in the liver regeneration after cirrhotic liver
resection. However, further studies will be necessary to
determine both its clinical impact and its exact mechanism
of action.
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